TOR (target of rapamycin) as an anti-cancer target

The mammalian target of rapamycin (mTOR) pathway is one of the major signalling pathways involved in the pathogenesis of cancer. An increased understanding of this pathway has enabled the development of newly targeted therapies against not only the mTOR complex itself but also upstream and downstream targets. In this review, we will focus on TOR inhibitors as anti-cancer therapies.

Section editors:Victoria Heath and Roy Bicknell – University of Birmingham, Institute for Biomedical Research, The Medical School, Edgbaston, Birmingham B15 2TT, UK